Downward Pressure on the Clinical Laboratory Testing Market from Healthcare Cost-Containment Policies and Medical Service Fee Revisions
First written in FY2016. 11 of 21 entries say "Restated". Latest entry: FY2026.
Techno Medica moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Although the 2026 medical reimbursement rate revision included a 3.09% increase in the core component, it was insufficient to support medical institutions' overall operations. Loss-making operations have become the norm at many hospitals, and more than half of hospitals continue to run at a loss.」
Although the core medical reimbursement rate was revised up by 3.09%, the increase was insufficient to support medical institutions overall, and the company stated that challenging conditions continue, with more than half of hospitals operating at a loss. - FY2026-H1WorsenedAnnual report
「In the healthcare industry, demand for medical services is rising further, while the operating environment for medical facilities remains extremely challenging due to higher material and utility costs, labor shortages and rising personnel expenses resulting from revisions to work schedules associated with work-style reforms in healthcare settings.」
The company states that, although demand for medical services is increasing, the operating environment for medical facilities is extremely challenging because of higher material and utility costs, labor shortages and rising personnel expenses. External pressure on the healthcare market has intensified. - FY2025ReframedAnnual report
「Under the medical reimbursement rate revision effective 1 April 2024, the increase in the core component was limited to 0.88%. Including the drug price revision, overall medical reimbursement rates were revised down for the second consecutive time, and the operating environment for medical institutions remains challenging.」
The explanation of the medical reimbursement rate revision was updated from a 0.43% increase in the core component in the 2022 revision to a 0.88% increase in the core component in the 2024 revision. Overall rates, including drug prices, were nevertheless described as having been revised down again. - FY2024RestatedAnnual report
「Under the medical reimbursement rate revision effective 1 April 2022, the increase in the core component was limited to 0.43%. Including the drug price revision, overall medical reimbursement rates were revised down for the second consecutive time, and the operating environment for medical institutions remains challenging.」
The company continues to disclose the 0.43% increase in the core component of the 2022 medical reimbursement rate revision, the overall downward revision including drug prices, and the challenging operating environment for medical institutions. - FY2023ReframedAnnual report
「Under the latest medical reimbursement rate revision, effective 1 April 2022, the increase in the core component was limited to 0.43%. Including the drug price revision, overall medical reimbursement rates were revised down for the second consecutive time, and the operating environment for medical institutions remains challenging.」
The explanation was updated from the previous description of a 0.46% net decrease in the 2020 revision to a description of the 2022 revision as a 0.43% increase in the core component and a decrease overall, including drug prices. - FY2022RestatedAnnual report
「Under the latest medical reimbursement rate revision, effective 1 April 2020, the net revision was a decrease of 0.46%, and the operating environment for medical institutions remains challenging.」
The company continues to disclose the 0.46% net downward revision and the challenging operating environment for medical institutions as external pressure on the clinical testing market. - FY2021RestatedAnnual report
「Under the medical reimbursement rate revision effective 1 April 2020, the net revision was a decrease of 0.46%, and the operating environment for medical institutions remains challenging.」
The company continues to disclose the 0.46% net downward revision and the challenging operating environment for medical institutions as external pressure on the clinical testing market. - FY2020MitigatedAnnual report
「Under the medical reimbursement rate revision effective 1 April 2020, the net revision was a decrease of 0.46%, and the operating environment for medical institutions remains challenging.」
The net medical reimbursement rate was revised down by 0.46%, narrowing the decrease from the previous 1.19% reduction. However, the company states that the operating environment for medical institutions remains challenging. - FY2020-Q2RestatedAnnual report
「In the medical equipment industry, as containing medical spending remains a policy priority, the circumstances surrounding the provision of medical care continue to be subject to renewed scrutiny.」
The company has reconfirmed its view of the market environment that containing medical spending remains a policy priority and that the provision of medical care is being subject to renewed scrutiny. - FY2020-Q1RestatedAnnual report
「In the medical equipment industry, as containing medical spending remains a policy priority, the circumstances surrounding the provision of medical care continue to be subject to renewed scrutiny.」
The company has reconfirmed its view of the market environment that containing medical spending remains a policy priority and that the provision of medical care is being subject to renewed scrutiny. - FY2019RestatedAnnual report
「Under the medical reimbursement rate revision effective 1 April 2018, the net revision was a decrease of 1.19%, and the operating environment for medical institutions remains challenging.」
The company continues to disclose pressure on medical institutions and the clinical testing market from the net downward revision to medical reimbursement rates and policies to contain medical spending. - FY2019-Q3RestatedAnnual report
「In the medical equipment industry, as the government advances its efforts to restrain social security spending, medical reimbursement rates have also been revised down on a net basis, requiring medical facilities to improve operating efficiency further.」
The company continues to recognize that efforts to restrain social security spending and the net downward revision to medical reimbursement rates require medical facilities to improve operating efficiency. - FY2019-Q1WorsenedAnnual report
「In the medical equipment industry, as the government advances its efforts to restrain social security spending, medical reimbursement rates have also been revised down on a net basis, requiring medical facilities to improve operating efficiency further.」
The company indicates that efforts to restrain social security spending have advanced further and that medical reimbursement rates have also been revised down on a net basis, increasing pressure on medical facilities and the clinical testing market. - FY2018WorsenedAnnual report
「Under the medical reimbursement rate revision effective 1 April 2018, the net revision was a decrease of 1.19%, and the operating environment for medical institutions remains challenging.」
The net medical reimbursement rate was revised down by 1.19%, widening the decrease from the previous 0.84% reduction. Market pressure from efforts to contain medical spending is intensifying. - FY2017RestatedAnnual report
「Under the revision of medical fees effective 1 April 2016, the net revision rate was negative 0.84%, and the operating environment for medical institutions remains difficult.」
The company continues to recognize market pressure from the 0.84% downward revision to the net medical reimbursement rate and policies to contain medical spending. - FY2017-Q3RestatedAnnual report
「In Japan’s healthcare sector, as the government’s Basic Policy on Economic and Fiscal Management and Reform clearly sets out a policy of curbing the growth of social security expenditure, policies to contain healthcare costs have continued to be promoted, including a net revision rate of negative 0.84% combining the revisions to the basic medical fee and drug prices effective 1 April 2016, and difficult conditions have persisted.」
The company has reiterated that the net reimbursement rate was revised down by 0.84% and that policies to contain medical spending remain in place, with external pressure on the clinical testing market considered unchanged. - FY2017-Q2RestatedAnnual report
「In Japan’s healthcare sector, as the government’s Basic Policy on Economic and Fiscal Management and Reform clearly sets out a policy of curbing the growth of social security expenditure, policies to contain healthcare costs have continued to be promoted, including a net revision rate of negative 0.84% combining the revisions to the basic medical fee and drug prices effective 1 April 2016, and difficult conditions have persisted.」
The company continues to recognize the external pressure on the clinical testing market from the downward revision to medical reimbursement rates and ongoing policies to contain medical spending. - FY2017-Q1RestatedAnnual report
「In Japan’s healthcare sector, as the government’s Basic Policy on Economic and Fiscal Management and Reform clearly sets out a policy of curbing the growth of social security expenditure, policies to contain healthcare costs have continued to be promoted, including a net revision rate of negative 0.84% combining the revisions to the basic medical fee and drug prices effective 1 April 2016, and difficult conditions have persisted.」
The company has reiterated that the net reimbursement rate was revised down by 0.84% and that policies to contain medical spending remain in place, with pressure on medical institutions and the clinical testing market considered unchanged. - FY2016MaterialisedAnnual report
「Under the revision of medical fees effective 1 April 2016, the net revision rate was negative 0.84%, and the operating environment for medical institutions remains difficult.」
The net revision rate for medical fees of negative 0.84% is presented as a specific external factor, with its impact on medical institutions and the clinical testing market identified as a risk.